

From: [John Whalan](#)
To: [Danielle DeVoney](#)
Cc: [Barbara Glenn](#); [Ravi Subramaniam](#)
Subject: Fw: Cxt-Adjustment from acute to chronic
Date: 10/26/2011 08:25 AM
Attachments: [MDI MoA Review.pdf](#)

Danielle,

I received this paper from Juergen Pauluhn just a few minutes ago. The subject for his Email is "Cxt-Adjustment from acute to chronic." The title of his paper is *Interrelating the acute and chronic mode of action of inhaled methylenediphenyl diisocyanate (MDI) in rats assisted by computational toxicology*. I have not had time to read it, but I thought about you and our discussion on Monday re Cxt. Considering that MDI is an irritant, there may be parallels for formaldehyde.

John

----- Forwarded by John Whalan/DC/USEPA/US on 10/26/2011 08:13 AM -----

From: juergen.pauluhn@bayer.com
To: John Whalan/DC/USEPA/US@EPA
Date: 10/26/2011 06:29 AM
Subject: Cxt-Adjustment from acute to chronic

Dear John,

attached you receive my latest publication which may be of interest to you.

Mit freundlichen Grüßen - Kind Regards

Juergen

Bayer HealthCare

Bayer Pharma AG
Global Drug Discovery - Global Early Development
Aprather Weg 18a, build. 514
D-42096 Wuppertal, Germany

Phone: +49 202 36 3909
Mobile: +49 1753103909
Fax: +49 202 36 4589
E-mail: juergen.pauluhn@bayer.com
Web: <http://www.bayerscheringpharma.de>

Vorstand: Andreas Fibig, Vorsitzender | Manfred Vehreschild, Hartmut Klusik
Vorsitzender des Aufsichtsrats: Richard Pott
Sitz der Gesellschaft: Berlin | Eintragung: Amtsgericht Charlottenburg HRB 283 B



MDI_MoA_Review.pdf